← Leaderboards
Merrill J Egorin
University Of Pittsburgh At Pittsburgh
$3,657,275
Attributed
$3,657,275
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2005–10$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$3,657,275 · 5
By mechanism
N01$2,053,427 · 2
U01$914,153 · 1
P30$378,167 · 1
P41$311,528 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Jan Hendrik Beumer$5,486,814
- Chandra Belani$1,686,281
- Ramesh Ramanathan$303,574
Others in their field
Top investigators on “Protein Isoforms”
- Randall J Bateman · Washington University$79,170,583
- Rolf Apweiler · European Molecular Biology Laboratory$41,336,566
- Stanley B Prusiner · University Of California San Francisco$33,187,893
- Howard Y Chang · Stanford University$26,252,541
- David A Bennett · Rush University Medical Center$25,855,566
- Yadong Huang · J. David Gladstone Institutes$24,532,318
Research focus
Protein IsoformsCytochrome P450Drug KineticsLaboratoriesPharmacodynamicsBiologicalPharmaceutical PreparationsDrug MetabolismEnzymesMolecularDoseDesignMethodologyPharmacologyAnimalsProgramsMetabolismAntineoplastic AgentsPharmacokinetic ModelBiochemicalAnimal TissueClinical TrialsProtein BindingResearch Personnel
Grant awards (17)
Preclinical Pharmacological Studies of Antitumor & Other Therapeutic Agents$886,790
N01 · FY2010 · CA · contact PI
Preclinical Pharmacological Studies of Antitumor & Other Therapeutic Agents$509,715
N01 · FY2010 · CA · contact PI
Preclinical Pharmacological Studies of Antitumor & Other Therapeutic Agents$465,760
N01 · FY2009 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis$235,564
U01 · FY2009 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis$250,000
U01 · FY2008 · CA · contact PI
CORE--CLINICAL PHARMACOLOGY ANALYTICAL FACILITY$114,572
P30 · FY2008 · CA · contact PI
Phase I Clinical Trials of Novel Anticancer Agents$428,589
U01 · FY2007 · CA · contact PI
CORE--CLINICAL PHARMACOLOGY ANALYTICAL FACILITY$124,160
P30 · FY2007 · CA · contact PI
CORE--CLINICAL PHARMACOLOGY ANALYTICAL FACILITY$47,652
P30 · FY2006 · CA · contact PI
CORE--CLINICAL PHARMACOLOGY ANALYTICAL FACILITY$46,534
P30 · FY2005 · CA
CORE--CLINICAL PHARMACOLOGY ANALYTICAL FACILITY$45,249
P30 · FY2004 · CA
MODELING IN ANTI CANCER DRUG DVMT PRECLINICAL STUDIES THOUGH CLINICAL TRIALS$155,764
P41 · FY2002 · RR
MODELING IN ANTI CANCER DRUG DVMT PRECLINICAL STUDIES THOUGH CLINICAL TRIALS$155,764
P41 · FY2001 · RR
PRECLINICAL PHARMACOLOGICAL STUDIES OF ANTITUMOR AND ANT$159,302
N01 · FY2000 · CM
PRECLINICAL PHARMACOLOGICAL STUDIES OF ANTITUMOR AND ANT$31,860
N01 · FY2000 · CM
MODELING IN ANTI CANCER DRUG DVMT PRECLINICAL STUDIES THOUGH CLINICAL TRIALS$0
P41 · FY2000 · RR
PRECLINICAL PHARMACOLOGICAL STUDIES OF ANTITUMOR AND ANT$0
N01 · FY2000 · CM